Get the Stockscreener App
1.55
0.00%
0.00
After Hours:
1.54
-0.01
-0.65%
Geron Corp stock is traded at $1.55, with a volume of 22.16M.
It is up +0.00% in the last 24 hours and down -19.27% over the past month.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
See More
Previous Close:
$1.55
Open:
$1.53
24h Volume:
22.16M
Relative Volume:
1.62
Market Cap:
$992.84M
Revenue:
$183.88M
Net Income/Loss:
$-85.78M
P/E Ratio:
-12.04
EPS:
-0.1287
Net Cash Flow:
$-110.95M
1W Performance:
-3.13%
1M Performance:
-19.27%
6M Performance:
+17.42%
1Y Performance:
-8.82%
1-Day Range:
$1.44
$1.56
1-Week Range:
$1.44
$1.72
52-Week Range:
$1.04
$2.01
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.55 | 992.84M | 183.88M | -85.78M | -110.95M | -0.1287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Geron Details RYTELO Growth Plan, $220M-$240M 2026 Sales Guide and MF Trial Catalyst at Barclays Conference - Yahoo Finance
Geron (NASDAQ:GERN) Shares Up 8.5%Should You Buy? - MarketBeat
Geron (NASDAQ:GERN) Stock Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Geron Corporation (GERN) Reports Q4 EPS of (5c) - Insider Monkey
Geron at Barclays Healthcare Conference: Strategic Growth and Future Plans - Investing.com
How The Geron (GERN) Story Is Shifting After Target Cut And New Equity Plans - Yahoo Finance
11 Fastest Growing Penny Stocks to Buy Right Now - Insider Monkey
Geron (NASDAQ:GERN) Trading Up 10.9%Here's What Happened - MarketBeat
Geron Corporation $GERN Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
Soleus files 5.2% stake in Geron (GERN) via master fund - Stock Titan
A Look At Geron (GERN) Valuation As Investors Weigh RYTELO Growth Against Recent Losses - simplywall.st
Is Geron (GERN) Using Its New ATM Program To Prioritize Flexibility Over Shareholder Dilution? - Yahoo Finance
Geron at TD Cowen: Strategic Growth and Market Expansion - Investing.com
Geron (NASDAQ: GERN) launches $150M ATM sales agreement with TD Cowen - Stock Titan
Geron 10-K: Revenue $183.9M, EPS (0.13) - TradingView
HC Wainwright Issues Optimistic Outlook for Geron Earnings - MarketBeat
Geron (GERN) 2025 Revenue Surges to $183.6M Driven by RYTELO Commercial Success - Yahoo Finance
Geron Corporation (NASDAQ:GERN) Q4 2025 Earnings Call Transcript - Insider Monkey
Geron (GERN) Pops on FDA Nod: Is This Small-Cap Biotech Now Underpriced? - AD HOC NEWS
HC Wainwright Weighs in on Geron's Q2 Earnings (NASDAQ:GERN) - MarketBeat
Geron shares drop after Q4 results miss estimates despite Rytelo growth - MSN
Geron Corp (GERN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments - Investing.com Canada
Geron Corp (GERN) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Geron (GERN) Projects Strong Revenue and Manages Expenses for 20 - GuruFocus
Why Geron (GERN) Is Up 8.3% After Narrowing Losses And Boosting 2026 RYTELO Outlook - simplywall.st
Geron Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Geron (NASDAQ:GERN) Releases Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Why Did GERN Stock Tumble 10% Pre-Market Today? - Stocktwits
Geron Q4 Earnings Call Highlights - MarketBeat
Geron Corporation (GERN) Shares Plummet After Missing Q4 2025 Ex - GuruFocus
Earnings call transcript: Geron Q4 2025 results miss forecasts, stock plunges - Investing.com
Geron (GERN) Targets RYTELO Growth with Strategic Actions in 202 - GuruFocus
Geron: Overview of Fourth Quarter Financial Results - Bitget
Geron earnings missed by $0.02, revenue fell short of estimates - Investing.com
GERON ($GERN) Releases Q4 2025 Earnings - Quiver Quantitative
Geron: Q4 Earnings Snapshot - Barchart.com
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - TradingView
RYTELO drives Geron (GERN) 2025 revenue surge and 2026 guidance - Stock Titan
Geron Corporation Reports $184 Million in RYTELO® Revenue for 2025 and Provides 2026 Financial Guidance - Quiver Quantitative
Earnings Summary: Geron Q4 - Benzinga
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Assessing Geron (GERN) Valuation After Recent Short Term Share Price Momentum - Yahoo Finance
Geron Corp. Stock Hits Day Low of $1.72 Amid Price Pressure - Markets Mojo
Geron (GERN) Set to Announce Q4 Earnings - GuruFocus
Geron (NASDAQ:GERN) Stock Price Up 8.8%Still a Buy? - MarketBeat
Geron Corporation Q4 Financial Announcement Sparks Investor Curiosity - StocksToTrade
Is Geron (GERN) Pricing Look Attractive After Recent Share Price Rebound? - Yahoo Finance
Geron earnings up next: Can RYTELO sustain revenue momentum? By Investing.com - Investing.com South Africa
Geron earnings up next: Can RYTELO sustain revenue momentum? - Investing.com
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):